BAUSCH & LOMB's $97 MIL. CASH PURCHASE OF DR. MANN PHARMA
BAUSCH & LOMB's $97 MIL. CASH PURCHASE OF DR. MANN PHARMA, a West German ophthalmic drug company, will introduce the U.S. eyecare company to the European ophthalmic drug market. "The acquisition is the most significant development thus far in Bausch & Lomb's program for establishing a major presence in the worldwide ophthalmic pharmaceutical business," the company said in a July 7 press release. Approximately half of Dr. Mann's $26 mil. annual volume is made up of Rx ophthalmics with the other half coming from OTC personal health care products, Bausch & Lomb said. Roughly 90% of Dr. Mann's business is conducted in West Germany and the remainder in other European countries. According to Bausch & Lomb, Dr. Mann's chief Rx product is the beta blocker BetaMann (metipranolol), which is used in the treatment of glaucoma. The German firm has a U.S. licensing agreement with CooperVision, which has the drug in clinical trials. Dr. Mann Pharma will operate as a separate subsidiary of Bausch & Lomb with present management remaining in place. The company is headed by Erika Schwalbe-Riel. Bausch & Lomb took its initial plunge into the U.S. drug business last March when it purchased 10 Rx and OTC ophthalmic products from Muro Pharmaceutical. The company also has an anti-allergy drug in its research pipeline, human IgE pentapeptide, which is licensed from Immunetech for ophthalmic indications. The drug is currently in Phase II trials.
More from Archive
More from Pink Sheet
Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.
Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.
With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.